BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 10468042)

  • 21. Pathogenesis and Therapy of Primary Cutaneous T-Cell Lymphoma: Collegium Internationale Allergologicum (CIA) Update 2020.
    Bobrowicz M; Fassnacht C; Ignatova D; Chang YT; Dimitriou F; Guenova E
    Int Arch Allergy Immunol; 2020; 181(10):733-745. PubMed ID: 32690848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cutaneous T cell lymphoma: update on treatment.
    Wollina U
    Int J Dermatol; 2012 Sep; 51(9):1019-36. PubMed ID: 22909354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-Cell Lymphomas.
    Dusílková N; Bašová P; Polívka J; Kodet O; Kulvait V; Pešta M; Trněný M; Stopka T
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29036928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Malignant lymphoma of the skin].
    Burg G; Dommann S; Dummer R
    Ther Umsch; 1993 Dec; 50(12):828-34. PubMed ID: 8171405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
    Vidulich KA; Talpur R; Bassett RL; Duvic M
    Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Granulomatous slack skin disease: a review, in comparison with mycosis fungoides.
    Shah A; Safaya A
    J Eur Acad Dermatol Venereol; 2012 Dec; 26(12):1472-8. PubMed ID: 22435618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive analysis of cutaneous T-cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy.
    Ghazawi FM; Netchiporouk E; Rahme E; Tsang M; Moreau L; Glassman S; Provost N; Gilbert M; Jean SE; Pehr K; Sasseville D; Litvinov IV
    Cancer; 2017 Sep; 123(18):3550-3567. PubMed ID: 28493286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cutaneous T Cell Lymphoma: A Difficult Diagnosis Demystified.
    Peterson E; Weed J; Lo Sicco K; Latkowski JA
    Dermatol Clin; 2019 Oct; 37(4):455-469. PubMed ID: 31466586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cutaneous T-cell lymphoma: epidemiology, etiology, and classification.
    Willemze R
    Leuk Lymphoma; 2003; 44 Suppl 3():S49-54. PubMed ID: 15202525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myocosis fungoides--an update on a non-mycotic disease.
    Makdisi J; Friedman A
    J Drugs Dermatol; 2013 Jul; 12(7):825-31. PubMed ID: 23884501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lymphoma-associated hemophagocytic syndrome (LAHS) in advanced-stage mycosis fungoides/Sézary syndrome cutaneous T-cell lymphoma.
    Blom A; Beylot-Barry M; D'Incan M; Laroche L
    J Am Acad Dermatol; 2011 Aug; 65(2):404-410. PubMed ID: 21550694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary cutaneous T-cell lymphomas in childhood and adolescence.
    Wohlmuth-Wieser I
    J Dtsch Dermatol Ges; 2021 Apr; 19(4):563-581. PubMed ID: 33861015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of cutaneous T-cell lymphomas: Established and emergent therapies.
    Wain T; Venning VL; Consuegra G; Fernandez-Peñas P; Wells J
    Australas J Dermatol; 2019 Aug; 60(3):200-208. PubMed ID: 30809800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cutaneous T-cell lymphoma: CT in evaluation and staging.
    Bass JC; Korobkin MT; Cooper KD; Kane NM; Platt JF
    Radiology; 1993 Jan; 186(1):273-8. PubMed ID: 8416579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Current therapy concepts in cutaneous T-cell lymphomas].
    Nestle FO; Häffner AC; Schmid MH; Dummer R; Burg G
    Schweiz Med Wochenschr; 1997 Feb; 127(8):311-20. PubMed ID: 9157537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histopathology and genetics of cutaneous T-cell lymphoma.
    Smoller BR; Santucci M; Wood GS; Whittaker SJ
    Hematol Oncol Clin North Am; 2003 Dec; 17(6):1277-311. PubMed ID: 14710885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Staging and management of cutaneous T-cell lymphoma.
    Scarisbrick JJ
    Clin Exp Dermatol; 2006 Mar; 31(2):181-6. PubMed ID: 16487086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Second Primary Malignancies in CTCL Patients from 1992 to 2011: A SEER-Based, Population-Based Study Evaluating Time from CTCL Diagnosis, Age, Sex, Stage, and CD30+ Subtype.
    Amber KT; Bloom R; Nouri K
    Am J Clin Dermatol; 2016 Feb; 17(1):71-7. PubMed ID: 26386881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL).
    Litvinov IV; Netchiporouk E; Cordeiro B; Doré MA; Moreau L; Pehr K; Gilbert M; Zhou Y; Sasseville D; Kupper TS
    Clin Cancer Res; 2015 Jun; 21(12):2820-9. PubMed ID: 25779945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.